Sun Pharmaceutical Industries Ltd (SUNPHARMA) — Announcement | 1 October 2026

1 October 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Sun Pharma to present LEQSELVI long-term alopecia areata data at EADV 2026

💡 Investor Takeaway

Routine procedural filing with no direct impact on shareholders.

⚠️ Risks

Serious infections, blood clots, and potential increased cardiovascular risk with JAK inhibition noted in safety profile

Sun Pharmaceutical announced that LEQSELVI (deuruxolitinib) will be featured in seven presentations at the 2026 EADV Congress, including a featured oral presentation reporting up to two years of safety and efficacy data in severe alopecia areata. Long-term data show 93.9% of baseline responders maintained response at Week 108 and 96.8% of previously nonresponsive patients achieved response by Week 52 and sustained it through Week 108. Safety remained consistent with no deaths, thrombosis, or major cardiovascular events reported in the studied population.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹4,36,678.96 CrP/E: 36.1ROE: 14.5%ROCE: 18.7%Div Yield: 0.88%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does LEQSELVI's efficacy compare to existing alopecia areata treatments?""What is the market potential for LEQSELVI in the severe alopecia areata patient population?""When will LEQSELVI be available for prescription in major markets?"

Ask AI Free →

📊 More SUNPHARMA filings

🟡 Corporate Governance — 29 September 2026Sun Pharmaceutical Industries Ltd submitted its ESG Overview for FY 2025-26, detailing governance ch...
🟡 Voting Results — 28 September 2026Sun Pharmaceutical Industries announced the completion of its postal ballot dated 25 August 2026, co...
🔴 Announcement — 28 September 2026Sun Pharma announced a global licensing deal with LIB Therapeutics for lerodalcibep, a PCSK9 inhibit...
🟡 Shareholding Pattern — 26 September 2026Sun Pharmaceutical Industries announced that shareholders approved reclassifying the promoter group ...
Announcement — 25 September 2026Sun Pharmaceutical announces that its trading window will close on 1 October 2026 and remain shut un...

See all SUNPHARMA filings →

🔥 Also filed on 1 October 2026

GOPALGopal Snacks LtdAnnouncement PVPPVP Ventures LtdAnnouncement GCSLGretex Corporate Services LtdOffer Document AVALONAvalon Technologies LtdInsider Trading VIYASHViyash Scientific LtdCorporate Action 501261Lords Mark Industries LimitedInsider Trading

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.